Ajaypal Singh to Anemia
This is a "connection" page, showing publications Ajaypal Singh has written about Anemia.
Connection Strength
17.117
-
Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). Am J Nephrol. 2023; 54(1-2):1-13.
Score: 0.823
-
The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
Score: 0.805
-
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
Score: 0.784
-
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
Score: 0.779
-
Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO. Am J Nephrol. 2022; 53(5):361-365.
Score: 0.778
-
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
Score: 0.754
-
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
Score: 0.754
-
Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019 11; 28(6):600-606.
Score: 0.656
-
Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? Nat Rev Nephrol. 2012 Nov; 8(11):616-8.
Score: 0.401
-
What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):420-4.
Score: 0.347
-
Diabetes, anemia and CKD: Why TREAT? Curr Diab Rep. 2010 Aug; 10(4):291-6.
Score: 0.345
-
The etiology of anemia in heart failure. Preface. Heart Fail Clin. 2010 Jul; 6(3):xvii-xviii.
Score: 0.343
-
Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. Heart Fail Clin. 2010 Jul; 6(3):323-32.
Score: 0.343
-
Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol. 2010; 31(6):552-6; discussion 563-4.
Score: 0.341
-
ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol. 2010 Apr; 21(4):543-6.
Score: 0.337
-
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
Score: 0.336
-
Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol. 2010 Jan; 21(1):2-6.
Score: 0.331
-
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46.
Score: 0.328
-
Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol. 2009 Jul; 20(7):1436-41.
Score: 0.320
-
The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Am J Kidney Dis. 2008 Dec; 52(6 Suppl):S5-13.
Score: 0.308
-
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008; 110(4):c244-50.
Score: 0.306
-
Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95.
Score: 0.304
-
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8.
Score: 0.299
-
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90.
Score: 0.298
-
Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008 Sep; 74(5):679-83.
Score: 0.293
-
The optimal hemoglobin in dialysis patients- a critical review. Semin Dial. 2008 Jan-Feb; 21(1):1-6.
Score: 0.289
-
Anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2008 Jan; 3(1):3-6.
Score: 0.288
-
Does correction of anemia slow the progression of chronic kidney disease? Nat Clin Pract Nephrol. 2007 Dec; 3(12):638-9.
Score: 0.285
-
Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim.
Score: 0.284
-
Anemia of chronic kidney disease: CHOIR and the FDA. Nat Clin Pract Nephrol. 2007 Aug; 3(8):406-7.
Score: 0.279
-
The FDA black box for EPO: what should nephrologists do? Nephrol News Issues. 2007 May; 21(6):55-6, 58-9.
Score: 0.276
-
Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 May-Jun; 13(3):251-9.
Score: 0.276
-
Anaemia of CKD--the CHOIR study revisited. Nephrol Dial Transplant. 2007 Jul; 22(7):1806-10.
Score: 0.274
-
The target hemoglobin in patients with chronic kidney disease. Nephrol News Issues. 2006 Dec; 20(13):29-30.
Score: 0.268
-
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98.
Score: 0.267
-
Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease. Med Clin North Am. 2005 May; 89(3):549-61.
Score: 0.240
-
The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease. Nephrol Nurs J. 2005 Mar-Apr; 32(2):199-206; quiz 207-8.
Score: 0.237
-
Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. N Engl J Med. 2022 12 29; 387(26):2482-2485.
Score: 0.204
-
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
Score: 0.198
-
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
Score: 0.154
-
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol. 2017; 46(6):488-497.
Score: 0.144
-
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
Score: 0.143
-
Prevalence of vitamin D deficiency in Saudi adults. Saudi Med J. 2013 Aug; 34(8):814-8.
Score: 0.106
-
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
Score: 0.105
-
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
Score: 0.101
-
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401.
Score: 0.097
-
Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61.
Score: 0.097
-
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
Score: 0.095
-
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
Score: 0.087
-
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
Score: 0.082
-
Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis. 2009 Sep; 54(3):498-510.
Score: 0.080
-
Posttransplant anemia: the role of sirolimus. Kidney Int. 2009 Aug; 76(4):376-82.
Score: 0.080
-
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
Score: 0.080
-
Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol. 2009 Mar; 24(3):431-4.
Score: 0.075
-
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9.
Score: 0.072
-
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar; 18(3):975-84.
Score: 0.068
-
Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med. 2005; 6 Suppl 3:S35-41.
Score: 0.059
-
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13.
Score: 0.015